Utility of Oral Valganciclovir for Cytomegalovirus Prophylaxis: Does It Improve Treatment Compliance?

Transplantation Proceedings

Volumn 40, Issue 9, 2008, Pages 3063-3064

  Moro, J A ^a,b   Almenar, L ^b   Martinez Dolz L ^b   Blanes, M ^a   Aguero J ^b   Sanchez Lazaro I ^b   Salvador, A ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b Heart Failure and Transplant Unit   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG USE; FEMALE; HEALTH BEHAVIOR; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPHYLAXIS;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SELECTION; RETROSPECTIVE STUDIES;

EID: 55749098775     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.09.052     Document Type: Article

References (8)

1. Paya C.V., and Razonable R.R. Cytomegalovirus infection after solid organ transplantation. In: Bowden R.A., Ljungman P., and Paya C.V. (Eds). Transplant infections. 2nd ed. (2003), Lippincott Williams and Wlkins, Philadelphia 298
2. Egan J.J., Carroll K.B., Yonan N., et al. Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial. J Heart Lung Transplant 21 (2002) 460
3. Antretter H., Höfer D., Hangler H., et al. Is it possible to reduce CMV-infections after heart transplantation with a three-month antiviral prophylaxis?. 7 years experience with ganciclovir. Wien Klin Wochenschr 116 (2004) 542
4. Vrtovec B., Thomas C.D., Radovancevic R., et al. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients. J Heart Lung Transplant 23 (2004) 461
5. Antretter H., Höfer D., Klaus A., et al. Cytomegalovirus infection after heart transplantation. Retrospective analysis of an antiviral CMV prevention. Dtsch Med Wochenschr 125 (2000) 445
6. Devyatko E., Zuckermann A., Ruzicka M., et al. Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation. J Heart Lung Transplant 23 (2004) 1277
7. Egan J.J., Lomax J., Barber L., et al. Preemptive treatment for the prevention of cytomegalovirus disease in lung and heart transplant recipients. Transplantation 65 (1998) 747
8. Asberg A., Humar A., Rollag H., et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 7 (2007) 2106